The Reflex That Turns Down Inflammation: A Pivotal Trial of Vagus Nerve Stimulation in Rheumatoid Arthritis

Key Takeaways:

• The vagus nerve carries a hardwired brake on inflammation: acetylcholine acting at the alpha-7 nicotinic receptor on macrophages suppresses their release of tumor necrosis factor, and this circuit is dysregulated in rheumatoid arthritis.
• In the pivotal RESET-RA trial of 242 patients who had already failed biologic or targeted synthetic DMARDs, 35.2 percent reached an ACR20 response on active stimulation versus 24.2 percent on sham at three months.
• Response rates rose to 52.8 percent by twelve months in open-label follow-up, and the only serious device-related events were perioperative and resolved.

Vagus nerve stimulation for rheumatoid arthritis sounds implausible until you follow the anatomy. The nervous system does not merely register inflammation; it regulates it. Two decades ago, work published in Nature established that stimulating the vagus nerve rapidly suppresses macrophage release of tumor necrosis factor, and identified the receptor doing the work: the alpha-7 subunit of the nicotinic acetylcholine receptor, sitting on the surface of the macrophage itself. The proof was elegant. Electrical stimulation of the vagus shut down TNF synthesis in normal mice and failed entirely in mice lacking that alpha-7 subunit. This circuit, the inflammatory reflex, is a standing brake on cytokine production, and in rheumatoid arthritis the brake is not working properly.

RESET-RA asked whether restoring that brake changes disease. It was a pivotal, double-blind, sham-controlled trial of an implanted vagus-targeted neuromodulation device in 242 patients — importantly, patients who had already had an inadequate response to, or could not tolerate, biologic or targeted synthetic disease-modifying drugs. This is the population where options thin out. Everyone was implanted; participants were randomized to active or sham stimulation for three months, after which all crossed to open-label stimulation. At three months, 35.2 percent of the active group achieved an ACR20 response against 24.2 percent on sham, meeting the primary endpoint. In open-label follow-up, response rates climbed to 50.0 percent at six months and 52.8 percent at twelve. Adverse events were comparable between arms, and device-related serious adverse events occurred in 1.6 percent, all perioperative and all resolved.

What does vagus nerve stimulation for rheumatoid arthritis actually offer patients?

Read the numbers honestly and the picture is encouraging rather than triumphant. The margin over sham at three months was about eleven percentage points, and the more impressive twelve-month figures come from open-label follow-up with no control group left to compare against — natural history, expectation, and regression to the mean all remain in play there. What makes the result meaningful is the context: these were patients whose drugs had already failed, and the intervention adds no further immunosuppression, which is the central cost of nearly every effective RA therapy. It is also worth being clear about what this is not. This is a surgically implanted device delivering defined stimulation to the cervical vagus, and it should not be confused with the humming, gargling, and breathing exercises marketed as vagus nerve hacks. Those practices influence autonomic tone and have their own modest merits, but they have never been shown to reproduce anything like this effect on cytokine biology. The deeper significance of RESET-RA may be conceptual: a neural circuit, properly targeted, can behave like a drug.

References:

1. Tesser, J. R. P., Crowley, A. R., Box, E. J., June, J. P., Wickersham, P. B., Valenzuela, G. J., et al. (2026). Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: A pivotal randomized controlled trial. Nature Medicine, 32(1), 369-378.
2. Wang, H., Yu, M., Ochani, M., Amella, C. A., Tanovic, M., Susarla, S., et al. (2003). Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature, 421(6921), 384-388.
3. Koopman, F. A., Chavan, S. S., Miljko, S., Grazio, S., Sokolovic, S., Schuurman, P. R., et al. (2016). Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America, 113(29), 8284-8289.